Trial · NCT05039086
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
NCT05039086, Completed, Brigham and Women's Hospital; results first posted 2024-02-20
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5. Trials, record NCT05039086. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05039086
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
- NCT number
- NCT05039086
- Status
- Completed
- Enrollment
- 13,021 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PDE5 inhibitor, Endothelin Receptor Antagonists
- First posted
- 2021-09-09
- Last updated
- 2025-08-06
- Results first posted
- 2024-02-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Dementia Onset | Median follow up times: 1) 168 days (exp), 151 days (ref) 2) 693 days (exp), 720 days (ref) 3) 382 days (exp), 358 days (ref) 4) 169 days (exp), 151 days (ref) | Time to dementia onset includes: Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition. Analysis 1-'as-treated' follow-up approach: In this approach, we followed patients from cohort entry until treatment discontinuation or switch to the comparator treatment, insurance disenrollment, death, or administrative endpoint (December 2018). Treatment discontinuation was defined as occurring 90 days after the expected days supply. of the most recently filled prescription to accommodate suboptimal adherence during treatment periods. Analysis 2-'as-started' follow-up approach incorporating a 6-month 'induction' period. Analysis 3-incorporating a 6-month 'symptoms to diagnosis' period Analysis 4-high-specificity outcome definition Study accessed Medicare files (Jan 2008-Dec 2018) between September 1, 2021 to October 4, 2022. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Dementia Onset | Median follow up times: 1) 168 days (exp), 151 days (ref) 2) 693 days (exp), 720 days (ref) 3) 382 days (exp), 358 days (ref) 4) 169 days (exp), 151 days (ref) | Study cohort after 1:1 propensity score matching | Incidence rate per 1000 person year | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Dementia Onset | PDE5 Inhibitors | Analysis 1 | 17.9 | 95% Confidence Interval 13.5 to 23.4 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Endothelin Receptor Antagonists | Analysis 1 | 18.8 | 95% Confidence Interval 14.3 to 24.3 | Incidence rate per 1000 person year |
| Time to Dementia Onset | PDE5 Inhibitors | Analysis 2 | 19.8 | 95% Confidence Interval 15.2 to 25.4 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Endothelin Receptor Antagonists | Analysis 2 | 19.9 | 95% Confidence Interval 15.3 to 25.4 | Incidence rate per 1000 person year |
| Time to Dementia Onset | PDE5 Inhibitors | Analysis 3 | 15.1 | 95% Confidence Interval 10.2 to 21.4 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Endothelin Receptor Antagonists | Analysis 3 | 22.6 | 95% Confidence Interval 16.5 to 30.1 | Incidence rate per 1000 person year |
| Time to Dementia Onset | PDE5 Inhibitors | Analysis 4 | 5.2 | 95% Confidence Interval 3 to 8.4 | Incidence rate per 1000 person year |
| Time to Dementia Onset | Endothelin Receptor Antagonists | Analysis 4 | 4.7 | 95% Confidence Interval 2.7 to 7.8 | Incidence rate per 1000 person year |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PDE5 Inhibitors | 9,968 | |
| Overall Study | STARTED | Endothelin Receptor Antagonists | 3,053 | |
| Overall Study | COMPLETED | PDE5 Inhibitors | 2,888 | |
| Overall Study | COMPLETED | Endothelin Receptor Antagonists | 2,888 | |
| Overall Study | NOT COMPLETED | PDE5 Inhibitors | 7,080 | |
| Overall Study | NOT COMPLETED | Endothelin Receptor Antagonists | 165 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PDE5 Inhibitors | 327 | 2,888 |
| Total, all-cause mortality | Endothelin Receptor Antagonists | 407 | 2,888 |
| Total, other adverse events | PDE5 Inhibitors | 0 | 2,888 |
| Total, other adverse events | Endothelin Receptor Antagonists | 0 | 2,888 |
| Total, serious adverse events | PDE5 Inhibitors | 0 | 0 |
| Total, serious adverse events | Endothelin Receptor Antagonists | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| PDE5 Inhibitors vs Endothelin Receptor Antagonists: deaths from any cause |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05039086
GET https://conductscience.org/api/trials/v1/NCT05039086/registered